Brind.

AstraZeneca invests $1bn in new R&D center in Cambridge, Massachusetts

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AstraZeneca is investing $1 billion to establish a new strategic R&D center in Kendall Square, Cambridge, Massachusetts. This facility, which spans 570,000 square feet, will combine the company’s research into biopharmaceuticals, oncology, and rare diseases. The company announced the center's opening via LinkedIn.

From healthcare-digital.com

Why it matters

Some supportBrind's analysis of the reports

The investment supports AstraZeneca’s strategy to achieve US$80 billion in total revenue by 2030, with the company expecting 50% of that revenue to come from the United States. This new center will help accelerate the discovery and development of new medicines.

From healthcare-digital.com

Who's involved

  • AstraZenecaPharmaceutical company making the $1bn investment in R&D infrastructure.
  • CambridgeLocation of the new strategic R&D center in Cambridge, Massachusetts.
  • LinkedInPlatform used by AstraZeneca to announce the opening of the new R&D center.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped